News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Civitas Therapeutics Announces Positive Phase 2b Results For CVT-301, Inhaled Levodopa For The Treatment Of Parkinson’s Disease



4/28/2014 9:29:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHELSEA, Mass.--(BUSINESS WIRE)--Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa). Study results from Phase 2 studies will be presented at the 66th Annual American Academy of Neurology Meeting on April 29, 2014 at 2:30pm ET in Philadelphia, PA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES